This formulation along with NLG919, a indoleamine-2,3-dioxygenase inhibitor, was used to treat B16-OVA-melanoma tumor-bearing mice and showed synergistic inhibition of tumor growth by activation of immune system and regulation of tumor microenvironment (TME) [19]. Here, IDO2 is linked to neoplasm.